These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of agents to reduce infarct size: it can be quite REVEALing. Bhatt DL JAMA; 2011 May; 305(18):1908-9. PubMed ID: 21558525 [No Abstract] [Full Text] [Related]
4. Epoetin: for better or for worse? Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601 [No Abstract] [Full Text] [Related]
5. Targeting anemia with erythropoietin during critical illness. Cook D; Crowther M N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850 [No Abstract] [Full Text] [Related]
6. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
7. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
8. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease. Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080 [TBL] [Abstract][Full Text] [Related]
9. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Li J; Xu H; Gao Q; Wen Y Eur J Clin Pharmacol; 2012 May; 68(5):469-77. PubMed ID: 22086550 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients. Levine AM; Salvato P; Leitz GJ; AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320 [TBL] [Abstract][Full Text] [Related]
11. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473 [No Abstract] [Full Text] [Related]
12. Successful recombinant erythropoietin therapy for a developing anemic newborn with hereditary spherocytosis. Hosono S; Hosono A; Mugishima H; Nakano Y; Minato M; Okada T; Takahashi S; Harada K Pediatr Int; 2006 Apr; 48(2):178-80. PubMed ID: 16635181 [No Abstract] [Full Text] [Related]
13. Epoetin alfa: to give or not to give. Dang C; Hudis C; Norton L J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203 [No Abstract] [Full Text] [Related]
14. Use of epoetin in chronic renal failure. Coyne DW JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149 [No Abstract] [Full Text] [Related]
16. Amgen's point of view on epoetins. Seidenberg B; Perlmutter RM Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950 [No Abstract] [Full Text] [Related]
17. [Should erythropoietin be administered to old patients in the preoperative period of orthopaedics surgery?]. Páramo Fernández JA Med Clin (Barc); 2004 Oct; 123(11):421-2. PubMed ID: 15482717 [No Abstract] [Full Text] [Related]
18. Erythropoiesis-stimulating agents: development, detection and dangers. Franz SE Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203 [TBL] [Abstract][Full Text] [Related]